Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
46.23
0.00 (0.00%)
At close: Nov 26, 2025, 1:00 PM EST
46.25
+0.02 (0.04%)
Pre-market: Nov 28, 2025, 4:02 AM EST
Collegium Pharmaceutical Stock Forecast
Stock Price Forecast
The 5 analysts that cover Collegium Pharmaceutical stock have a consensus rating of "Strong Buy" and an average price target of $45.4, which forecasts a -1.80% decrease in the stock price over the next year. The lowest target is $37 and the highest is $50.
Price Target: $45.4 (-1.80%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Collegium Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 3 | 3 | 3 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $45 → $48 | Strong Buy | Maintains | $45 → $48 | +3.83% | Nov 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $44 → $46 | Strong Buy | Maintains | $44 → $46 | -0.50% | Nov 7, 2025 |
| Needham | Needham | Strong Buy Reiterates $46 | Strong Buy | Reiterates | $46 | -0.50% | Oct 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $44 | Strong Buy | Initiates | $44 | -4.82% | Aug 11, 2025 |
| Piper Sandler | Piper Sandler | Hold Reiterates $36 → $37 | Hold | Reiterates | $36 → $37 | -19.97% | May 9, 2025 |
Financial Forecast
Revenue This Year
766.66M
from 631.45M
Increased by 21.41%
Revenue Next Year
791.77M
from 766.66M
Increased by 3.28%
EPS This Year
9.07
from 1.86
Increased by 388.67%
EPS Next Year
8.51
from 9.07
Decreased by -6.24%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 792.8M | 828.4M | ||||
| Avg | 766.7M | 791.8M | ||||
| Low | 731.8M | 736.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 25.5% | 8.0% | ||||
| Avg | 21.4% | 3.3% | ||||
| Low | 15.9% | -3.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 10.99 | 11.99 | ||||
| Avg | 9.07 | 8.51 | ||||
| Low | 7.17 | 6.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 492.1% | 32.2% | ||||
| Avg | 388.7% | -6.2% | ||||
| Low | 286.4% | -28.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.